Viruses (Feb 2024)

Advances of Recombinant Adenoviral Vectors in Preclinical and Clinical Applications

  • Luca Scarsella,
  • Eric Ehrke-Schulz,
  • Michael Paulussen,
  • Serge C. Thal,
  • Anja Ehrhardt,
  • Malik Aydin

DOI
https://doi.org/10.3390/v16030377
Journal volume & issue
Vol. 16, no. 3
p. 377

Abstract

Read online

Adenoviruses (Ad) have the potential to induce severe infections in vulnerable patient groups. Therefore, understanding Ad biology and antiviral processes is important to comprehend the signaling cascades during an infection and to initiate appropriate diagnostic and therapeutic interventions. In addition, Ad vector-based vaccines have revealed significant potential in generating robust immune protection and recombinant Ad vectors facilitate efficient gene transfer to treat genetic diseases and are used as oncolytic viruses to treat cancer. Continuous improvements in gene delivery capacity, coupled with advancements in production methods, have enabled widespread application in cancer therapy, vaccine development, and gene therapy on a large scale. This review provides a comprehensive overview of the virus biology, and several aspects of recombinant Ad vectors, as well as the development of Ad vector, are discussed. Moreover, we focus on those Ads that were used in preclinical and clinical applications including regenerative medicine, vaccine development, genome engineering, treatment of genetic diseases, and virotherapy in tumor treatment.

Keywords